Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Company Overview

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s portfolio is centered on vonoprazan, a potassium-competitive acid blocker designed to suppress gastric acid production and provide an alternative to traditional proton pump inhibitors.

Phathom markets vonoprazan in the United States under the brand name Voquezna. The product is approved for the healing and maintenance of healing of erosive esophagitis, relief of associated heartburn, and treatment of heartburn related to non-erosive gastroesophageal reflux disease. Voquezna is also approved, in combination with antibiotics, for the eradication of Helicobacter pylori, a bacterium associated with peptic ulcers and other gastrointestinal conditions.

Phathom was established in 2018 and obtained U.S. rights to develop and commercialize vonoprazan through an agreement with Takeda Pharmaceutical Company. The company is headquartered in Buffalo Grove, Illinois, and is led by Chief Executive Officer Terrie Curran. Its commercial activities are primarily focused on the U.S. gastrointestinal market.

Key Stats

• Today's Range: $6.65 to $7.00
• 50-Day Range: $6.70 to $11.66
• 52-Week Range: $6.64 to $18.31
• Volume: 1.10 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $542.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.25
• Consensus Rating: Moderate Buy

Phathom Pharmaceuticals Stock Analysis - MarketRank™

Phathom Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 234th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Phathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Phathom Pharmaceuticals has a consensus price target of $21.25, representing about 217.2% upside from its current price of $6.70.

Amount of Analyst Coverage

Phathom Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.27) to $1.16 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.85% of the float of Phathom Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 9.11.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently decreased by 6.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phathom Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phathom Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.33

News Sentiment

Phathom Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.33% of the stock of Phathom Pharmaceuticals is held by insiders.

Percentage Held by Institutions

99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PHAT
• CIK: 1783183
• Web: www.phathompharma.com
• Phone: 877-742-8466
• Fax: N/A
• Employees: 371
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Phathom Pharmaceuticals: $21.25
• High Price Target: $28.00
• Low Price Target: $10.00
• Potential Upside/Downside: +217.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$221.25 million
• Net Margins: -41.34%
• Pretax Margin: -41.34%
• Return on Equity: N/A
• Return on Assets: -20.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $175.11 million
• Price / Sales: 3.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.14) per share
• Price / Book: -1.09

Miscellaneous

• Outstanding Shares: 80,900,000
• Free Float: 73,353,000
• Market Cap: $542.03 million
• Optionable: Optionable
• Beta: 0.50